UK agency says Pfizer breast cancer drug too expensive

LONDON (Reuters) - Pfizer's breast cancer drug Ibrance, or palbociclib, is too expensive to justify its use on Britain's state-run health service, the country's healthcare cost-effectiveness watchdog said on Friday.

The National Institute for Health and Care Excellence (NICE) said in draft guidance that although the medicine was likely to offer some improvement in overall survival, this could not be quantified from clinical trials.

"Even when allowing for these potential benefits, it was still not enough to make palbociclib cost effective at its current price," Carole Longson, director of NICE's center for health technology assessment, said in a statement on Friday.

Ibrance's list price is 2,950 pounds ($3,700) per 28 days.

Pfizer UK's oncology head David Montgomery noted that the NICE decision was not final decision and said the U.S. drugmaker was committed to working to try and find a solution to make the drug available.

(Reporting by Ben Hirschler, editing by Pritha Sarkar)

Related News

GE, Boeing, Oracle form coalition to support Republican border tax

Feb 3, 2017

US-USA-TRUMP-COMPANIES-TAX:GE, Boeing, Oracle form coalition to support Republican border tax

Iowa moves to cut Medicaid funding for Planned Parenthood

Feb 3, 2017

US-IOWA-PLANNEDPARENTHOOD:Iowa moves to cut Medicaid funding for Planned Parenthood

SpaceX says fix underway for rocket turbine wheel cracking

Feb 2, 2017

US-SPACE-SPACEX:SpaceX says fix underway for rocket turbine wheel cracking

Must Read

China raises short-term interest rates in fresh tightening sign

Feb 3, 2017

US-CHINA-ECONOMY-RATES:China raises short-term interest rates in fresh tightening sign

Cardinals ink Martinez to five-year deal

Feb 3, 2017

US-BASEBALL-MLB-STL-MARTINEZ:Cardinals ink Martinez to five-year deal

Ford upbeat on local sales despite safety recall in South Africa

Feb 3, 2017

US-SAFRICA-FORD:Ford upbeat on local sales despite safety recall in South Africa

Obserworld delivers the most accurate and up-to-date world news for the global audience with a thorough research and in-depth interviews. Discover the world through Obserworld.

Contact us: sales@obserworld.com